 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Thomas Flaig and Corbin Eule.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.925 |
|
|
|
-
Eule CJ, Warren A, Molina Kuna E, Robin TP, Gershman B, Kim SP, Flaig TW. Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database. Prostate Cancer Prostatic Dis. 2025 Jun; 28(2):444-450.
Score: 0.958
-
Eule CJ, Warren A, Molina Kuna E, Callihan EB, Kim SP, Flaig TW. Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen. Urology. 2024 06; 188:118-124.
Score: 0.921
-
Jones MK, Nicklawsky A, Shortt J, Pattee J, Kennerley V, Eule CJ, Candelario N, O'Donnell PH, Flaig TW. Pharmacogenomics of chemotherapy induced peripheral neuropathy using an electronic health record-derived definition: a genome-wide association study. Support Care Cancer. 2025 Apr 08; 33(5):362.
Score: 0.246
-
Callihan EB, Kuna EM, Eule CJ, Kessler ER, Flaig TW. Practice patterns and outcomes of conventional versus split-dose cisplatin in neoadjuvant ddMVAC in bladder cancer. Bladder Cancer. 2025 Jan-Mar; 11(1):23523735241310388.
Score: 0.243
-
Eule CJ, Kuna EM, Robin TP, Gershman B, Flaig TW, Kim SP. Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database. Urol Oncol. 2024 Dec; 42(12):447.e17-447.e24.
Score: 0.235
-
Eule CJ, Flaig TW, Wong K, Graf R, Lam ET. Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations. Prostate Cancer Prostatic Dis. 2023 03; 26(1):188-193.
Score: 0.208
-
Wiesen BM, Flaig TW, Gershman B, Konety B, Warren A, Kuna EM, Robin T, Kessler ER, Eule CJ, Breyer BN, Achua J, Kim SP. Racial Disparities in Clinical Trial Enrollment Among Patients Diagnosed With Prostate Cancer: A Population-Based Cohort of Oncology Practices. Adv Urol. 2024; 2024:8871425.
Score: 0.060
-
Kessler ER, Callihan E, Hu J, Eule C, Srivastava G, Kemme DJ, Iruku P, Rana V, Moore J, Schuster SR, Amirault M, Flaig TW, Lam ET. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma. Cancer Res Commun. 2023 06; 3(6):1004-1012.
Score: 0.054
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|